Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease

Journal of Neuroimmunology

Volumn 291, Issue , 2016, Pages 115-124

  Sil, Susmita ^a   Ghosh, Tusharkanti ^a  

^a UNIVERSITY OF CALCUTTA   (India)

Author keywords

Colchicine; Cox 2; Memory; Neurodegeneration; Neuroinflammation; PGE2

Indexed keywords

COLCHICINE; CYCLOOXYGENASE 2; ETORICOXIB; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; PYRIDINE DERIVATIVE; SULFONE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; MALE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT MODEL; REFERENCE MEMORY; WORKING MEMORY; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENCEPHALITIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MAZE TEST; METABOLISM; NEURODEGENERATIVE DISEASES; TIME FACTOR;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; COGNITION DISORDERS; COLCHICINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALITIS; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; NEURODEGENERATIVE DISEASES; PLAQUE, AMYLOID; PYRIDINES; RATS; SULFONES; TIME FACTORS;

EID: 84959335580     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.12.003     Document Type: Article

References (40)

1. Aloisi F. Immune function of microglia. Glia 2001, 36:165-179.
2. Anand R., Kumar A., Chidambaranathan N., Christina A.J.M., Kodagali1 R., Tyagi1 M.G. Influence of selective cox-2 inhibitor etoricoxib against MPTP induced striatal lesions in the rats. World J. Pharm. Pharm. Sci. 2013, 2:2029-2043.
3. Austin S.A., Combs C.K. Mechanisms of microglial activation by amyloid pre-cursor protein and its proteolytic fragments. Central Nervous System Diseases and Inflammation 2008, 13-32. Springer, London. T.E. Lane, M. Carson, C. Bergmann, T. Wyss-Coray (Eds.).
4. Bensimon G., Chermat R. Microtubule disruption and cognitive defects: effect of colchicine on learning behavior in rats. Pharmacol. Biochem. Behav. 1991, 38:141-145.
5. Brooks P., Kubler P. Etoricoxib for arthritis and pain management. Ther. Clin. Risk Manag. 2006, 2:45-57.
6. Caggiano A.O., Kraig R.P. Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1beta production. J. Neurochem. 1999, 72:565-575.
7. Combrinck M., Williams J., De Berardinis M.A., Warden D., Puopolo M., Smith A.D., Minghetti L. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2006, 77:85-88.
8. Cox G. Neuropathological techniques. Theory & Practice of Histological Techniques 1977, 258-259. Elsevier, London. J.D. Bancroft, A. Stevens (Eds.).
9. Csölle C., Sperlagh B. Peripheral origin of IL-1β production in rodent hippocampus under in vivo systemic bacterial lipoplysaccharide (LPS) challenge and regulation by P2X7 receptors. J. Neuroimmunol. 2010, 219:38-46.
10. Csölle C., Sperlagh B. Endo-cannabinergic modulation of IL-1β in mouse hippo-campus under basal conditions and after in vivo systemic lipopolysaccharide stimulation. Neuroimmunomodulation 2011, 18:226-231.
11. Dargahi L., Nasiraei-Moghadam S., Abdi A., Khalaj L., Moradi F., Ahmadiani A. Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Aβ-induced neuroinflammation. J. Mol. Neurosci. 2011, 45:10-21.
12. Dhull D.K., Jindal A., Dhull R.K., Agarwal S., Bhateja D., Padi S.S.V. Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer's Disease in rats. J. Mol. Neurosci. 2012, 46:223-235.
13. Duggan K.C., Walters M.J., Musee J., Harp J.H., Kiefer J.R., Oates J.A., Marnett L.J. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J. Biol. Chem. 2010, 285:34950-34959.
14. Emerich D.F., Walsh T.J. Cholinergic cell loss and cognitive impairments following intraventricular or intradentate injection of colchicine. Brain Res. 1990, 517:157-167.
15. Gehrmann J., Matsumoto Y., Kreutzberg G.W. Microglia: intrinsic immune effector cell of the brain. Brain Res. Rev. 1995, 20:269-287.
16. Hecker M., Foegh M.L., Ramwell P.W. The eicosanoids: prostaglandins, thromboxanes, leukotrienes and related compounds. In Basic and Clinical Pharmacology 1995, 290-304. Appleton & Lange, Norwalk, CT. B.G. Katzung (Ed.).
17. Ho L., Osaka H., Aisen P.S., Pasinetti G.M. Induction of cyclooxygenase COX/-2 but not COX-1 gene expression in apoptotic cell death. J. Neuroimmunol. 1998, 89:142-149.
18. Kumar A., Seghal N., Naidu P.S., Padi S.S.V., Goyal R. Colchicine induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacol. Rep. 2007, 59:274-283.
19. Kumar A., Seghal N., Padi S.S.V., Naidu P.S. Differential effects of cyclooxygenase inhibitors on intracerebroventricularcolchicine induced dysfunction and oxidative stress in rats. Eur. J. Pharm. 2006, 551:58-66.
20. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
21. Mallat M., Chamak B. Brain macrophages: neurotoxic or neurotrophic effector cells?. J. Leukoc. Biol. 1994, 56:416-422.
22. Marley E., Poole S., Stephenson J.D. Prostaglandins and the central nervous system. Postgrad. Med. J. 1977, 53:649-651.
23. Mizuno M., Yamada K., Olariu A., Nawa H., Nabeshima T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J. Neurosci. 2000, 20:7116-7121.
24. Nadda N., Setia S., Vaish V., Sanyal S.N. Role of cytokines in experimentally induced lung cancer and chemoprevention by COX-2 selective inhibitor, etoricoxib. Mol. Cell. Biochem. 2013, 372:101-112.
25. Nogawa S., Takao M., Suzuki S., Tanaka K., Koto A., Fukuuchi Y., Hayakawa I. COX-2 expression in brains of patients with familial Alzheimer's disease. Int. Congr. Ser. 2003, 1252:363-372.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego.
27. Pitchaimani V., Arumugam S., Thandavarayan R.A., Thiyagarajan M.K., Aiyalu R., Sreedhar R., Nakamura T., Watanabe K. Nootropic activity of acetaminophen against colchicine induced cognitive impairment in rats. Clin. Biochem. Nutr. 2012, 50:241-244.
28. Rai S., Kamat P.K., Nath C., Shukla R. A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J. Neuroimmunol. 2013, 254:1-9.
29. Renner B., Walter G., Strauss J., Fromm M.F., Zacher J., Brune K. Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief. Eur. J. Pain 2012, 16:838-848.
30. Renner B., Zacher J., Buvanendran A., Walter G., Strauss J., Brune K. CSF, and wound tissue in patients following hip surgery-a pilot study. Schmiedebergs Arch. Pharmacol. 2010, 381:127-136.
31. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:986-1000.
32. Rodrigues M.L., Lamas N., Valle-Fernandes A., Cruz A., Vieira A., et al. The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment. Inflamm. Res. 2010, 59:743-753.
33. Shi J., Wang Q., Johansson J.U., Liang X., Woodling N.S., Priyam P., Loui T.M., Merchant M., Breyer R.M., Montine T.J. Andreasson K. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann. Neurol. 2012, 72:788-798.
34. Shigematsu K., McGeer P.L. Accumulation of amyloid precursor protein in neurons after intraventricular injection of colchicine. Am. J. Pathol. 1992, 140:787-794.
35. Sil S., Ghosh R., Sanyal M., Guha D., Ghosh T.K. A comparison of neurodegeneration linked with neuroinflammation in brain areas of rats after intracerebroventricular colchicine injection. J. Immunotoxicol. 2015, 10.3109/1547691X.2015.1030804.
36. Sil S., Goswami A.R., Dutta G., Ghosh T. Effects of naproxen on some immune responses in colchicine induced rat model of Alzheimer's disease. Neuroimmunomodulation 2014, 21:304-321.
37. Stevens A., Bancroft J.D. Proteins and nucleic acids. Theory and Practice of Histological Techniques 1977, 129. Elsevier, London. A. Stevens, J.D. Bancroft (Eds.).
38. 2signalling is implicated in inflammation early in the Alzheimer disease course. Nat. Rev. Neurol. 2012, 8:411.
39. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 1999, 830:226-236.
40. Zarghi A., Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran. J. Pharm. Res. 2011, 10:655-683.